Can I reuse my CE technical file for FDA?

In short: Partially. The evidence layer — bench testing, software V&V, clinical data, risk management, QMS — substantially reuses. The submission logic does not: FDA needs a pathway (usually 510(k) with a predicate and substantial-equivalence argument), which is built differently from an MDR conformity case. Plan the file for reuse from the start.

What genuinely transfers

Most of the substantive evidence generation behind a CE technical file is market-agnostic: bench and performance testing, software verification and validation, cybersecurity testing, clinical data (whether from your own investigation, equivalence, or literature), and your risk management file all describe properties of the device itself, not properties of a specific regulator's submission format. A well-built ISO 13485 quality management system similarly serves both markets directly, especially now that FDA's QMSR — in force since 2 February 2026 — incorporates ISO 13485:2016 by reference.

What has to be rebuilt

What doesn't transfer is the argument your submission makes. An MDR technical file demonstrates conformity against the General Safety and Performance Requirements, reviewed by a Notified Body against Annexes II and III. A 510(k) makes a substantial-equivalence argument against a specific predicate device, reviewed by FDA against a different evidentiary standard entirely. Even where the underlying evidence is identical, it has to be reorganized, and in places supplemented — FDA's human-factors and clinical-evidence expectations, for instance, often go beyond what a CE file contains — to fit the FDA submission's own logic, including finding and justifying a predicate, which has no MDR equivalent at all. And where no predicate exists, the pathway itself changes: novel low-to-moderate-risk devices go through De Novo, high-risk devices through PMA — each with its own argument structure again.

The planning implication

The costly mistake isn't reusing evidence across markets — that's the efficient path. It's building your evidence-generation programme with only one market's submission format in mind, then discovering during a second-market submission that testing protocols, documentation structure, or clinical evidence depth need meaningful rework to satisfy the other regulator. Founders planning a genuine multi-market strategy get more value from designing the underlying testing and documentation plan for dual use from the outset than from optimizing purely for whichever market they're pursuing first.

Where next: What a CE File Transfers to SFDA and the GCC · Does FDA clearance help me in Europe (or a CE mark in the US)?

Talk to us about designing one dossier for multiple markets. Book an expert conversation →